Publications, Abstracts, Presentations

Publications

  1. Magnetic Resonance Imaging of RRx-001 Pharmacodynamics in Preclinical Tumors Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Oncotarget. Advance Publications 2017, doi: 10.18632/oncotarget.18455.  
  2. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S Cabrales P, Summers Jr TA, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee M-J, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. Expert Opinion on Investigational Drugs 2017, 26, 109-119.  
  3. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl D. Clinical Epigenetics, 2017, 9, 4  
  4. Conversion of Platinum-Etoposide Resistant to Sensitive SCLC After Treatment with the Epi-immunotherapeutic, RRx-001: A Case Report Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Abrouk ND, Kim MM, Brown JL, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter C Oncology Research and Treatment 2016, 39, 720-723.  
  5. A Partial Response to Reintroduced Chemotherapy in a Resistant small Cell lung Cancer Patient after Priming with RRx-001. Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA. Clinical Medicine Insights: Oncology 2016,10, 105–108.  
  6. Partial Response in an RRx-001-Primed Patient with Refractory SCLC After a Third Introduction of Platinum Doublets Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C Case Rep Oncol 2016, 9(2), 285-289.  
  7. RRx-001, An Epigenetic-Based Radio- and Chemosensitizer, Has Vascular Normalizing Effects In SCCVII and U87 Tumors Oronsky B, Scicinski J, Cabrales P, Minchinton A. Clinical Epigenetics, 2016, 8, 53.  
  8. Turning On The Radio: Epigenetic Inhibitors As Potential Radiopriming Agents Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A Biomolecules 2016, 6, 32.  
  9. Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor- resistance and T790M-negative NSCLC Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C Respiratory Medicine Case Reports 2016, 18, 62-65.  
  10. A Look Inside The Mechanistic Black Box: Red Blood Cells Are The Critical Effectors Of RRx-001 Cytotoxicity Oronsky B, Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A. Med Oncol. 2016, 33, 63.  
  11. A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells Das DS, Ray A, Song Y, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC. Leukemia 2016, 30(11), 2187-2197.  
  12. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent, RRx-001 Carter C, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. Case Rep Oncol. 2016, 9, 164-170.  
  13. Addressing the Elephant in the Room, Therapeutic Resistance in Non-Small Cell Lung Cancer, with Epigenetic Therapies Carter C, Zeman K, Day R, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B. Oncotarget, 2016, 7(26), 40781-40791  
  14. Pulmonary Tumor Thrombotic Microangiopathy (PTTM): A New Paraneoplastic Syndrome? Carter C, Scicinski J, Lybeck H, Oronsky B. Case Rep Oncol 2016;9:246–248  
  15. RRx-001, A Novel Clinical-Stage Chemosensitizer, Radiosensitizer And Immunosensitizer Inhibits Glucose 6-Phosphate Dehydrogenase In Human Tumor Cells. Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P. Discovery Medicine, 2016, 21(116.), 251-65.  
  16. No Patient Left Behind: The Promise of Immune Priming With Epigenetic Agents Carter C, Oronsky B, Reid T, Scicinski J, Kim M, Oronsky A, Roswarski J. Oncoimmunology published online: http://dx.doi.org/10.1080/2162402X.2017.1315486.  
  17. Targeting Tumor Hypoxia with the Epigenetic Anticancer Agent, RRx-001, a Superagonist of Nitrite Reduction by Deoxyhemoglobin Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, Oronsky B. Med Oncol 2016, 33, 85.  
  18. RRx-001, A Novel Dinitroazetidine Radiosensitizer Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Investigational New Drugs, 2016, DOI 10.1007/s10637-016-0326-y, Published online 3 Feb 2016.  
  19. Rockets, Radiosensitizers and RRx-001: An Origin Story Part I Oronsky B, Scicinski J, Oronsky A, Ning S, Peehl D, Cabrales P, Bednarski M, Knox S. Discov Med. 2016, 21, 173-80.  
  20. RRx-001 in refractory small cell lung carcinoma: a case report of a partial response after a third reintroduction of platinum doublets Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Kim M, Oronsky A, Cabrales P, Oronsky N, Reid T, Brzezinski C, Roswarski J. Case Rep Oncol 2016, 9, 171-176. 
  21. Whole Brain Radiotherapy and RRx-001: Two Partial Responses In Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD. Trans Onc 2016, 9, 108-113.  
  22. Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J. Oncotarget 2016, 7(8), 9041-5.  
  23. The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis Carter CA, Browning R, Oronsky BT, Scicinski JJ, Brzezniak C. Case Rep Oncol 2016, 9, 68-75  
  24. Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C. Case Rep Oncol 2016, 9, 62-67.  
  25. Concurrent Whole Brain Radiotherapy and RRx-001 for Melanoma Brain Metastases Kim MM, Parmar H, Cao Y, Knox SJ, Oronsky B, Scicinski J, Lawrence TS, Lao CD. Neuro-Oncology 2016; 0, 1–2, doi:10.1093/neuonc/nov317  
  26. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl D. Oncotarget 2015, 5, 1–10.  
  27. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA: Case Rep Oncol 2016, 9, 45–50.  
  28. Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J. Case Rep Oncol, 2015, 8, 461-465.  
  29. Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man-PFS2: A Measure of Therapeutic Action-At-A-Distance Oronsky B, Carter CA, Reid T, Scicinski J Neoplasia 2015, 17, 716-722.  
  30. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris 3rd HA, Christopher Lao CD, Abrouk NED, Fanger GR, Infante JR. Lancet Oncol. 2015, 16, 1133–1142  
  31. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001 Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G. Redox Biol. 2015, 6, 1-8. doi: 10.1016/j.redox.2015.07.002.  
  32. Going viral: a review of replication-selective oncolytic adenoviruses Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. Oncotarget 2015, 21, 19976–19989.  
  33. A Review of Two Promising Radiosensitizers in Brain Metastases: RRx-001 and 2-Deoxyglucose Oronsky BT, Oronsky NC, Fanger GR, Lybeck MMC, Caroen SZ, Parker CW, Scicinski J. J Cancer Sci Ther, 2015, 07, 137-141. doi: 10.4172/1948-5956.  
  34. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria Yalcin O, Oronsky B, Carvalho LJ, Kuypers FA, Scicinski J, Cabrales P. Malar J. 2015, 14, 218. doi: 10.1186/s12936-015-0720-5. 
  35. Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001 Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R. Oncotarget. 2015, 6, 21547-21556 
  36. Impact of Hemoglobin Nitrite to Nitric Oxide Reductase on Blood Transfusion for Resuscitation From Hemorrhagic Shock Brouse C, Oritz D, Su Y, Oronsky B, Scicinski J, Cabrales P Asian J. Transfus. Sci. 2015, 9, 55.  
  37. Episensitization: Defying Time’s Arrow Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR. Front Oncol 2015, 5, 134. DOI: 10.3389/fonc.2015.00134  
  38. The war on cancer: a military perspective Oronsky B, Carter CA, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid, T. Front Oncol. 2014, 4, 387.  
  39. Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy Ning S, Bednarski M, Oronsky B, Scicinski J, Knox S. Biochem Biophys Res Comm, 2014, 447, 537.  
  40. Rewriting the Epigenetic Code for Tumor Resensitization: A Review Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T. Trans. Onc. 2014, 7, 626-631  
  41. Follow the ATP: Tumor energy production. A Perspective Oronsky B, Oronsky N, Fanger GR, Parker CW, Caroen SZ, Lybeck M, Scicinski J Anticancer Agents Med Chem 2014, 14, 1187–1198.  
  42. Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment Oronsky B, Oronsky N, Knox S, Fanger GR, Scicinski J. Anticancer Agents Med Chem, 2014, 14, 1187-1198  
  43. The Implications of Hyponitroxia in Cancer Oronsky B, Fanger GR, Oronsky N, Knox S, Scicinski J. Trans. Onc 2014, 7, 167  
  44. The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions Fens MH, Larkin SK, Oronsky B, Scicinski J, Morris CR, Kuypers FA. PLoS ONE 2014, 9, e101626.  
  45. Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J. Case Reports in Oncology, 2014, 7, 79.  
  46. Development of methods for the bioanalysis of RRx-001 and metabolites Scicinski J, Oronsky B, Cooper V, Taylor M, Alexander M, Hadar R, Cosford R, Fleischmann T, Fitch WL Bioanalysis, 2014, 6, 947.  
  47. Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, Scicinski J. Theranostics, 2013, 3, 437.  
  48. Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, et al. Drug Metab Dispos 2012, 40, 1810.  
  49. The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents Oronsky BT, Reid T, Knox SJ, Scicinski JJ Trans. Onc. 2012, 21, 226.  
  50. Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review Oronsky BT, Scicinski JJ, Reid T, Knox S. Trans. Onc. 2012, 5, 133.  
  51. Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ. Cancer. Res. 2012, 14, 2600.  
  52. Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review Oronsky B, Knox S, Scicinski J. Trans. Onc. 2012, 5, 66.  
  53. Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers Oronsky B, Knox S, Scicinski J. Trans. Onc. 2011, 4, 256.  
  54. Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation. Eichenbaum G, Hsu C-P, Subrahmanyam V, Chen J, Scicinski J, Galemmo RA Jr, et al.: J. Pharm. Sci. 2012, 30, 2545.  
  55. Light-fluorous safety-catch arylgermanes – exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling. Spivey, A. C.; Tseng, C.-C.; Hannah, J. P.; Gripton, C. J.; de Fraine, P.; Parr, N. J.; Scicinski, J. J.; Chem. Commun., 2007, 2926.  
  56. The development of a 'safety-catch' arylgermane for biaryl synthesis by palladium-catalysed germyl-Stille cross-coupling. Spivey, A. C.; Gripton, C. J.; Hannah, J. P.; Tseng, C.-C.; de Fraine, P.; Parr, N. J.; Scicinski, J. J.; Appl. Organomet. Chem. 2007, 21, 572.  
  57. Pre-clinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics. Eichenbaum, G.; Pollock-Dove, C.; Nguyen, Li, S.; J.; Evans, J.; Borghys, H.; Kennis, L.; Dong, L.; Van Osdol, W.; Dai, W.; Scicinski, J. J.; Chen, J.; Xu, Y.; Ashton, D.; Mackie, C.; Megens, A. J. Pharm. Sci. 2006, 95, 883.  
  58. Rapid one-pot preparation of 2-substituted benzimidazoles from 2-nitroanilines using microwave conditions. Van Vliet, D.; Gillespie, P.; Scicinski, J. J. Tetrahedron Lett. 2005, 46, 6741.
  59. Development of an indole safety-catch linker using analytical constructs. Scicinski, J. J.; Congreve, M. S.; Ley, S. V. J. Comb. Chem. 2004, 6, 375.  
  60. Microwave assisted saccharide coupling with n-pentenyl glycosyl donors. Mathew, F.; Jayaprakash, K. N.; Fraser-Reid, B.; Mathew, J.; Scicinski, J. J. Tetrahedron Lett. 2003, 44, 9051. 
  61. Versatile solid-phase synthesis of secondary amines from alcohols. Development of an N-Boc-(o-nitrobenzene)sulfonamide linker. Congreve, Miles S.; Kay, C.; Scicinski, J. J.; Ley, S. V.; Williams, G.; Murray, P. J.; McKeown, S. C.; Watson, S. P. Tetrahedron Lett. 2003, 44, 4153.  
  62. Analytical Methods for Solid Phase Organic Synthesis. Scicinski, J. J.; Congreve, M. S.; Kay, C.; Ley, S. V. Expedited article for Current Medicinal Chemistry. 2002, 9, 2103. 
  63. Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives. Wyatt, P. G.; Allen, M. J.; Chilcott, J.; Foster, A.; Livermore, D. G.; Mordaunt, J. E.; Scicinski, J. J.; Woollard, P. M. Bioorg. Med. Chem. Lett. 2002, 12, 1399.  
  64. Application of ReactArray Robotics and Design of Experiments Techniques in Optimization of Supported Reagent Chemistry. Jamieson, C.; Congreve, M. S.; Emiabata-Smith, D. F.; Ley, S. V.; Scicinski, J. J. Org. Process Research & Development 2002, 6, 823.  
  65. Analytical Construct Resins for Analysis of Solid Phase Chemistry. Congreve, M. S.; Scicinski, J. J.; Ley, S. V. Chem – Eur J. 2001, 8, 1769. 
  66. Solid-phase development of a 1-hydroxybenzotriazole linker for heterocycle synthesis using analytical constructs. Scicinski, J. J.; Congreve, M. S.; Jamieson, C.; Ley, S. V.; Newman, E. S.; Vinader, V. M.; Carr, R. A. J. Comb. Chem. 2001, 3, 387.  
  67. Development and application of a carbonyl-13C enriched BAL linker for solid phase reaction monitoring. Jamieson, C.; Congreve, M. S.; Hewitt, P. R.; Scicinski, J. J.; Ley, S. V. J. Comb. Chem. 2001, 3, 397.  
  68. Solid phase reaction monitoring – chemical derivatization and off-bead analysis. Kay, C.; Lorthioir, O.; Parr, N. J.; Congreve, M.; McKeown, S. C.; Scicinski, J. J.; Ley, S. V. Biotechnology and Bioengineering (Combinatorial Chemistry) 2001, 71, 110.  
  69. Reporter Resins for Solid-Phase Chemistry. Congreve, M. S.; Ladlow, M.; Marshall, P.; Parr, N.; Scicinski, J. J.; Sheppard, T.; Vickerstaffe, E.; Carr, R. A. E. Org. Lett. 2001, 3, 507.  
  70. Single bead characterization using analytical constructs: Application to quality control of libraries. Lorthioir, O.; Carr, R. A. E.; Congreve, M. S.; Geysen, H. M.; Kay, C.; Marshall, P.; McKeown, S. C.; Parr, N. J.; Scicinski, J J.; Watson, S. P. Anal. Chem. 2001, 73, 963.  
  71. Analysis of solid-phase reactions: product identification and quantification by use of UV-chromophore-containing dual-linker analytical constructs. Williams, G. M.; Carr, R. A. E.; Congreve, M. S.; Kay, C.; McKeown, S. C.; Murray, P. J.; Scicinski, J. J.; Watson, S. P. Angew. Chem., Int. Ed. 2000, 39, 3293.  
  72. Rapid reaction scanning of solid phase chemistry using resins incorporating analytical constructs. Murray, P. J.; Kay, C.; Scicinski, J. J.; McKeown, S. C.; Watson, S. P.; Carr, R. A. E. Tetrahedron Lett. 1999, 40, 5609.  
  73. Clean synthesis of a-bromo ketones and their utilization in the synthesis of 2-alkoxy-2,3-dihydro-2-aryl-1,4-benzodioxanes, 2-amino-4-aryl-1,3-thiazoles and piperidino-2-amino-1,3-thiazoles using polymer-supported reagents. Habermann, J.; Ley, S. V.; Scicinski, J. J.; Scott, J. S.; Smits, R.; Thomas, A. W. J. Chem. Soc., Perkin Trans. 1, 1999, 2425.  
  74. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides. Smith, P. W.; Sollis, S. L.; Howes, P. D.; Cherry, P. C.; Starkey, I. D.; Cobley, K. N.; Weston, H.; Scicinski, J.; Merritt, A.; Whittington, A.; Wyatt, P.; Taylor, N.; Green, D.; Bethell, R.; Madar, S.; Fenton, R. J.; Morley, P. J.; Pateman, T.; Beresford, A. J. Med. Chem. 1998, 41, 787.  
  75. The solid phase synthesis of a series of trisubstituted hydantoin ligands for the somatostatin SST5 receptor. Scicinski, J. J.; Barker, M. D.; Murray, P. J.; Jarvie, E. M. Bioorg. Med. Chem. Lett. 1998, 8, 3609.
  76.  Novel inhibitors of influenza sialidases related to GG167. Structure-activity, crystallographic and molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Smith, P. W.; Sollis, S. L.; Howes, P. D.; Cherry, P. C.; Cobley, K. N.; Weston, H.; Whittington, A. R.; Scicinski, J.; Bethell, R. C.; Taylor, N.; Skarzynski, T.; Cleasby, A.; Singh, O.; Wonacott, A.; Varghese, J.; Colman, P. Bioorg. Med. Chem. Lett. 1996, 6, 2931.  
  77. The squalestatins: preparation of C-4 carboxamide derivatives. Chan, C.; Scicinski, J. J.; Srikantha, A. R. P.; Watson, N. S. Tetrahedron Lett. 1996, 37, 8925.  
  78. The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors. Chan, C.; Andreotti, D.; Cox, B.; Dymock, B. W.; Hutson, J. L.; Keeling, S. E.; McCarthy, A. D.; Procopiou, P. A.; Ross, B. C.; Sareen, M.; Scicinski, J. J.; Sharratt, P. J.; Snowden, M.; Watson, N. S. J. Med. Chem. 1996, 39, 207.  
  79. Approaches to carbocyclic analogs of the potent neuraminidase inhibitor 4-guanidino-Neu5Ac2en. X-ray molecular structure of N-[(1S,2S,6R)-2-azido-6-benzyloxymethyl-4-formylcyclohex-3-enyl]acetamide. Chandler, M.; Conroy, R.; Cooper, A. W. J.; Lamont, R. B.; Scicinski, J. J.; Smart, J. E.; Storer, R.; Weir, N. G.; Wilson, R. D.; Wyatt, P. G. J. Chem. Soc., Perkin Trans. 1 1995, 1189.  
  80. Chemical libraries in drug discovery. Scicinski, J. J. Trends Biotechnol. 1995, 13, 246.  
  81. The squalestatins: Novel inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C-1 analogues. Procopiou, P. A.; Bailey, E. J.; Bamford, M. J.; Craven, A. P.; Dymock, B. W.; Hutson, J. L.; Kirk, B E.; McCarthy, A. D.; Sareen, M.; Scicinski, J. J.; Sharratt, P. J.; Snowden, M. A.; Watson, N. S.; Williams, R. J. J. Med. Chem. 1994, 37, 3274.  
  82. Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazoyl)-6-heptenoates and –heptanoates, a novel series of HMG-CoA reductase inhibitors. Chan, C.; Bailey, E. J.; Hartley, C. D.; Hayman, D. F.; Hutson, J. L.; Inglis, G. I.; Jones, P. S.; Kirk, B E.; Lamont, R. B.; Lester, M. G.; Pritchard, J. M.; Ross, B. C.; Scicinski, J. J.; Spooner, S. J.; Smith, G.; Steeples, I. P.; Watson, N. S. J. Med. Chem. 1993, 36, 3646.     

Book Chapters


  1. RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization Scicinski J, Oronsky B, Caroen S, Cabrales P, Summers TA, Reid TR, Kim MM, Trepel JB, Lee M-J, Abrouk ND, Day RM, Jha S, Oronsky A, Carter CA.  Cancer Sensitizing Agents for Chemotherapy ed. Bonavida, B, 2017     
  2. Discovery and Development of RRx-001, a Novel Nitric Oxide and ROS Mediated Epigenetic Modulator Scicinski J, Oronsky B, Ning S, Fanger GR, Knox SJ, Bednarski M. Nitric Oxide and Cancer: Pathogenesis and Therapy ed. Bonavida, B, 2015    
  3. Hyponitroxia in Cancer Oronsky B, Oronsky N, Lybeck M, Fanger G, Scicinski  J.  Nitric Oxide and Cancer: Pathogenesis and Therapy ed. Bonavida, B, 2015    
  4. ‘Episensitization: A New Word for A New Concept’  Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Fanger GR, Reid TR. Drug Discovery in Cancer Epigenetics ed. Egger G, Arimondo P  Academic Press, 2015     
  5. Approaches to Reaction Monitoring by Product Derivatization Congreve MS, Kay C, Scicinski J. Optimization of Solid-Phase Combinatorial Synthesis Hardcover ed Yan, B. Czarnik, AW. 2001    
  6. Optimization of solid-phase combinatorial synthesis. Congreve MS, Kay C, Scicinski JJ. Yan, B; Czarnik, A. W., Eds. Approaches to reaction monitoring by product derivatization, 1st ed.; Marcel Dekker: New York, 2001.    
  7. PS-Schwesinger base. Ley SV, Scicinski JJ.  Paquette, L. A.; Rigby, J.; Roush, W. R.; Wipf, P. eds. Electronic Encyclopedia of Reagents for Organic Synthesis Wiley: New York, 2001.   
       

Presentations and Abstracts

  1. Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis Jha S, Summers TA, Zeman K, Brzezniak C, Carter C, Fery L, Scicinski J, Oronsky B, Caroen S, Trepel JB, Cabrales P, Day R. AACR Annual Meeting; Washington, DC, USA; April 1–5, 2017. Abstract 966.   
  2. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry  Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM. AACR Annual Meeting; Washington, DC, USA; April 1–5, 2017. Abstract 4358.    
  3. Quadruple Threat: A pilot Phase 2 study of RRx-001 in advanced lung cancer prior to re-administration of platinum doublets  Zeman K, Brzezniak C, Trepel J, Day R, Abrouk N, Summers Jr TA, Fery L, Cabraales P, Jha S, Oronsky B, Scicinski J, Caroen S, Carter CA.  Journal of Thoracic Oncology 2017, 12(S1), P2.06-031   
  4. Sensitizing patients to Chemotherapy with RRx-001 Scicinski J (oral presentation)  World Precision Medicine Congress, Washington DC, USA, November 14-15, 2016   
  5. Clinical Anticancer Agent, RRx-001, protects From Doxorubicin-Induced Cardiotoxicity Oronsky B, Scicinski J, Cabrales P.  Circulation 2016, 134(S1), A12627.  
  6. Statistical analysis of episensitization using transition probability functions and PFS2 for “ROCKET”, a two stage phase II study of RRx-001, a multi-epigenetic agent, investigating resensitization to irinotecan in colorectal cancer  Abrouk N, Reid TR, Fisher GA, Carter CA, Thambi PM, Oronsky B, Fanger G, Caroen S, Parker C, Stirn M, Scicinski J*  ASCO GI 2016: J Clin Oncol 34, 2016 (suppl 4S; abstr TPS775)   
  7. The Hypoxia-Selective Epigenetic Agent, RRx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells Das DS, Ray A, Song Y, Richardson PG, Oronsky B, Scicinski J, Chauhan D, Anderson KC, Blood, 2015, 126 (23) 918. (oral presentation)   
  8. A first-in-human phase I study of RRx-001 with whole brain radiation for treatment of brain metastases: Early results from serial quantitative perfusion imaging  Kim MM, Parmar H, Cao Y, Pramanik P, Mammoser A, Junck L, Lawrence T, Knox SJ, Cabrales P, Carter C, Scicinski J, Caroen S, Oronsky B, Lao, CD. 2015 SNO-SCIDOT Joint conference on therapeutic delivery to the CNS, November 18-19, San Antonio TX, USA  
  9. RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model  Knox SJ, Ning S, Zhao H, Peehl D, Oronsky B, Scicinski J  2015 AACR-NCI-EORTC Molecular Targets and Cancer, November 5-9, 2015, Boston, MD.   
  10. RRx-001, a novel ROS-mediated epigenetic modulator: ‘Episensitization’ to previously failed therapies  Scicinski J, (Oral presentation) 4th International Conference on Translational Medicine, October 26-28, 2015, Baltimore, USA.    
  11. Restoring Efficacy of Immunotherapy Treatments in Oncology with Radical Oxygen and Nitrogen Based Epigenetic Drugs  Scicinski, J (Oral presentation) STEM CELLS, Regenerative Medicine Congress, Sept 2-3, 2015, Washington DC.    
  12. RRx-001 Oxidation of Redox Sensitive Protein Thiols in Tumors Measured by Gd-LC7-SH Enhanced MRI In Preclinical Tumor Models Raghunand N, Scicinski J, Oronsky B, Jagadish B, Mash EA, Korn RL ISMRM 23rd Annual Meeting & Exhibition, May 30 - June 5, 2015, Toronto, Ontario, Canada. Abstr 1932.    
  13. RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”  Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J.
    AACR Special Conference: Chromatin and Epigenetics in Cancer. September 24-27, 2015, Atlanta GA, USA.    
  14. RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy Zhao H, Ning S, Scicinski J, Oronsky B, Knox S, Peehl DM.  AACR Annual Meeting; Philadelphia, PA, USA; April 18–22, 2015. Abstract 3515.   
  15. Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer Carter C, Reid T, Fisher G, Cho-Phan C, Kunz P, Kaiser H, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J.  AACR 2015 Abstract Control Number: 8836 Ann Oncol. 2015 Mar;26(suppl 2):ii4-ii5.   
  16. The development of RRx-001, a novel nitric-oxide-mediated epigenetically active anticancer agent Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T Invited Presentation at 4th International Workshop on Nitric Oxide in Cancer Therapy, Mar 13 – 14, 2015, Seville, Spain   
  17. Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, showing resensitization to irinotecan in colorectal cancer Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J. 5th Clinical Epigenetics International Meeting. March 5th - 6th, 2015 - Düsseldorf, Germany   
  18. Early Results: “ROCKET” a phase II Study of RRx-001, a novel triple epigenetic inhibitor, Resensitization to Irinotecan in Colorectal Cancer Carter C, Reid T, Fisher G, Cho-Phan C, Kunz P, Kaiser H, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J. 13th International Congress on Targeted Anticancer Therapies: TAT 2015. Paris, France, mar 2-4, 2015.    
  19. RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study.  Reid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox SJ, Oronsky B, Caroen S, Parker C, Fanger G, Scicinski J. 17th Annual Symposium on Anti-Angiogenesis and immune therapies, La Jolla, Feb 19 - 21, 2015   
  20. RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study.  Reid T, Carney J, Beale K, Chan C, Nguyen H, Stirn M, Ning S, Knox S, Oronsky B, Scicinski J, Caroen S, Parker C, Fanger G, Fisher G.  AACR Translation of the Cancer Genome Conference, San Francisco, California, February 7 - 9, 2015   
  21. Anti-Myeloma Activity of a Novel Free Radical Inducer RRx-001 Das DS, Tian Z, Ray A, Ravillah D, Song Y, Richardson PG, Oronsky B, Scicinski J, Chauhan D, Anderson KC. Blood, 2014, 124 (21) 4712;  
  22. RRx-001 An EXO-based Epigenetic Anti-Cancer Agent in Phase 2 Clinical Trials Cabrales P, Reid T, Oronsky B, Scicinski J, Chauchan D, Parker C, Caroen S, Fanger G. ISEV2014 Educational Event: Extracellular Vesicles and Biofluid Biopsies/Companion Diagnostics Conference   
  23. A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent. Reid TR, Oronsky B, Infante JR, Burris HA, Scribner C, Knox SJ, Stephens JL, Fanger G, Scicinski J J Clin Oncol 2014 32:5s (suppl; abstr 2578)   
  24. Resensitization to Previous Chemotherapy with the Novel Hypomethylating Anticancer Agent RRx-001  Reid T, Knox SJ, Ning S, Peehl D, Oronsky B, Stephens J, Fanger G, Korn R, Dad S, Scicinski J 16th International Symposium on Anti-Angiogenic Therapy, La Jolla, Feb 6 - 8, 2014  
  25. RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models Raghunand N, Scicinski J, Oronsky B, Guntle G, Bruckheimer E, Korn R. Proceedings: AACR 105th Annual Meeting 2014-- Apr 5-9, 2014; San Diego, CA, Abstr 2068.   
  26. RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase Cabrales P, Oronsky B, Scicinski J Proceedings: AACR 105th Annual Meeting 2014-- Apr 5-9, 2014; San Diego, CA, Abstr 1420.  
  27. Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice Ning S, Sekar TV, Paulmurugan R, Scicinski J, Oronsky B, Peehl D, Knox SJ.  Proceedings: AACR 105th Annual Meeting 2014-- Apr 5-9, 2014; San Diego, CA, Abstr 906.   
  28. High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain Fitch B, McLaughlin T, Fens M, Scicinski J. 2013 American Chemical Society, Western Regional Meeting, Abstract WRM 267 (Oral presentation)  
  29. Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent. Reid T, Infante J, Paul A, Burris H, Oronsky B, Scribner C, Knox S, Stephens J, Santini J, Scicinski J. Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1 (LB-86) Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC   
  30. Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent. Reid T, Infante J, Paul A, Burris H, Oronsky B, Scribner C, Knox S, Stephens J, Santini J, Scicinski J. 15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013             
  31. RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA). Oronsky B, Ning S, Knox S, Cabrales P, Minchinton A, Kuypers F, Fens M, Santini J, Reid T, Scicinski J.  15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013   
  32. Antivascular activity of RRx-001 in SCCVII and U87 tumors. Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S. 15th International Symposium on Anti-Angiogenic Therapy, La Jolla, Jan 31- Feb 2, 2013  
  33. Activity observed in a phase I dose escalation trial of the hypoxia-activated, nitric oxide NO prodrug, RRx-001  Reid T, Infante JR, Burris III HA, Scribner C, Knox S, Oronsky B, Stephens J, Scicinski J.  ASCO GI 2013: J Clin Oncol 31, 2013 (suppl 4; abstr 241)   
  34. RRx-001, a Hypoxia Activated, Nitric Oxide generating cytotoxic agent: Phase 1 study results Scicinski J Presentation at 3rd International Workshop on Nitric Oxide in Cancer Therapy, May 31 – Jun3 1, 2013, Kingston Ontario   
  35. RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1 (4371) Proceedings: AACR 103rd Annual Meeting 2012-- Mar 31-Apr 4, 2012; Chicago, IL   
  36. Treatment with a Novel Dinitroazetidine, ABDNAZ, Improves Nitrite Reductase Activity of Sickle Red Blood Cells. Fens M, Larkin S, Scicinski J, Fitch W, Oronsky B, Kuypers F. Blood (ASH Annual Meeting Abstracts) 2012, 120: Abstract 3246    
  37. Disposition and Bioanalysis of RRx-001 Scicinski J, Oronsky B, Fitch WL, Adams C, Luo G, Marini J, Cooper V, Alexander M, Taylor MJ. CACO Mini symposium Mini symposium: Bioanalytical and analytical applications & problem investigation case studies, August 10, 2012, Foster City CA, USA.    
  38. NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. Fens M, Larkin S, Morris C, Fitch W, Scicinski J, Oronsky B, Kuypers F. Blood (ASH Annual Meeting Abstracts) 2011, 118: Abstract 2125             
  39. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox S.  Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, (676) Proceedings: AACR 102nd Annual Meeting 2011-- Apr 2-6, 2011; Orlando, FL   
  40. Disposition of 14C-RRx-001 in Rats after A Single Intravenous Administration and in Blood from Rats, Dogs, Monkeys, and Humans. Scicinski J, Oronsky B, Fitch W, Taylor M, Luo Gang, Musick T, Marini J, Adams C, Schicker M, Gohdes M, McKenzie D, Ridgewell R. ISSX Annual meeting 2011, Abstract P81   
  41. ORADUR: Oral Controlled-Release and Abuse-Deterrent Platform Drug Delivery Technology Scicinski J. (Oral presentation) 13th Annual Drug Delivery Partnerships, Las Vegas, 2009   
  42. Lipinski-Like Rules For Transdermal Delivery. Scicinski J, Audett J, Ghosh S, Yang H, Imbert D.  (Poster presentation) Abstracts of IBC Drug Discovery & Development of Innovative Therapeutics World Congress, Boston, 2007.  
  43. An Analytical Platform for Screening Reactivity Scicinski J. (Oral presentation) Invited oral presentation at the Gordon Research Conference on Combinatorial Chemistry, Queens College, Oxford, UK, Aug 2004.   
  44. An Experimental Platform for Reaction Optimization and Library Production. Scicinski J. (Poster presentation) Gordon Research Conference on Combinatorial Chemistry, Tilden School, July 2003.   
  45. An Experimental Platform for Reaction Optimization and Library Production. Scicinski J. (Poster presentation) Drug Discovery Technologies Conference (IBC), World Congress, Boston, Aug 2003.   
  46. Application of analytical constructs to the development of an indole safety-catch linker family for solid phase organic synthesis. Scicinski JJ, Congreve MS, Ley SV. (Oral presentation) Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002.   
  47. Analytical constructs in solid-phase organic synthesis: Applications to linker development.  Scicinski J. (Oral presentation) High Throughput Organic Synthesis Symposium, San Diego, USA, Feb 2001.   
  48. Analytical constructs in solid-phase organic synthesis: Applications to linker development.  Scicinski J. (Oral presentation) Departmental Symposium, Cambridge University, Cambridge, UK. Oct 2000.   
  49. Developing solid-phase reactions. Hydantoins and the application of dual-linker analytical constructs. Scicinski J. (Oral presentation) Southampton Solid-phase Chemistry Summer School, Southampton University, Southampton, UK, Sept 1999.   
  50. Developing solid-phase reactions. Hydantoins and the application of dual-linker analytical constructs. Scicinski, J. (Oral presentation) Departmental Seminar, Strathclyde University, Glasgow, UK. Oct 1999.   
  51. Carbocyclic neuraminidase inhibitors. Scicinski J. (Oral presentation) Royal Society of Chemistry Workshop on Organic Synthesis, University of Wales, Gregynog, Sept 1995.  
  52. Carbocyclic neuraminidase inhibitors. Scicinski J. (Oral presentation) Departmental Seminar, University College, London, UK. Oct 1995.  
  53. New Advances in Combinatorial Chemistry Solid Supports and Linkers. Scicinski J. (Oral presentations) Lectures to graduate students at Oxford and Edinburgh Universities, UK, on combinatorial chemistry as part of The Industrial Consortium to support the Combinatorial and Solid Phase Chemistry (ICCSP) University lectures program. (2001)   
  54. Amine releasing dual linker analytical constructs for facile monitoring of solid phase chemistry. Congreve MS, Kay C, Murray PJ, Scicinski JJ, Ley SV, McKeown SC, Watson SP, Carr RAE. (Abstract). Editor(s): Epton, R. Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Libraries: Peptides, Proteins and Nucleic Acids--Small Molecule Organic Chemistry Diversity, Collected Papers, International Symposium, 6th, York, United Kingdom, Aug. 31-Sept. 4, 1999 (2001), 217   
  55. Dual linker analytical constructs – rapid analysis for solid phase chemistry. Kay C, McKeown SC, Parr NJ, Lorthoir O, Watson SP, Congreve MS, Scicinski JJ. (Abstract). Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept 10-15 (2001), meeting date 2000, 177-178.    
  56. Regiospecific synthesis of tetra-substituted imidazoles as HMG-CoA reductase inhibitors.  Chan C, Chambers L, Ewan GB, Green RH, Keeling SE, Scicinski JJ, Stonehouse RD, Watson NS. (Poster abstract) Abstract A 036, New Synthetic Methods, International Conference on Organic Synthesis (ICOS-12), Venezia Lido, Italy, June 28th – July 2nd 1998.   
  57. The Squalestatins: Novel inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C1 modified analogues.  (Poster abstract) Procopiou PA, Bailey EJ, Bamford MJ, Craven AP, Dymock  BW, Houston JG, Hutson JL, Kirk BE, McCarthy AD, Sareen M, Scicinski JJ, Sharrat PJ, Snowden MA, Watson N.  6th Cyprus Conference on New Methods in Drug Research. Limassol, Cyprus, May 8-14th 1994   
  58. The Squalestatins: Decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors.  (Poster abstract) Chan C, Andreotti D, Cox B, Dymock BW, Hutson JL, Inglis GGA, Keeling SE, McCarthy AD, Procopiou PA, Ross BC, Sareen M, Scicinski JJ, Sharratt PJ, Snowden MA, Srikantha ARP, Watson NS. 6th Cyprus Conference on New Methods in Drug Research. Limassol, Cyprus, May 8-14th 1994  

Patents and Applications

  1. Organonitro thioether compounds and medical uses thereof  Scicinski J, Oronsky BT. US patent: 9,468,625   
  2. Organonitro thioether compounds and medical uses thereof  Scicinski J, Oronsky BT. US patent: 9,139,519   
  3. Acyclic organonitro compounds for use in treating cancer Scicinski J, Oronsky BT, Wardle R, Cannizzo, L, Straessler, NA. US patent: 8,664,247   
  4. Oral pharmaceutical dosage forms  Scicinski J, van Osdol WW, Su, H-C, Arenberg, MH, Shah, J. US patent: 9,616,055  
  5. Peptidase inhibitors  Royalty S, Burns JF, Scicinski JJ, Jagdmann GE, Foglesong RJ, Ring KG, Dyakonov T, Middlemiss D.  US Patent 7,842,707   
  6. Oral pharmaceutical dosage forms  Scicinski J, van Osdol WW, Su, H-C, Arenberg, MH, Shah, J. US patent application: 20160058746A1   
  7. Oral pharmaceutical dosage forms  Scicinski J, van Osdol WW, Su, H-C, Arenberg, MH, Shah, J. US patent application: 20140011842A1   
  8. Organonitro thioether compounds and medical uses thereof  Scicinski J, Oronsky BT. US patent application: 20140349988A1  
  9. Acyclic organonitro compounds for use in treating cancer Scicinski J, Oronsky BT, Wardle R, Cannizzo, L, Straessler, NA. US patent application: 20130053418A1   
  10. Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto Oronsky BT, Knox S, Scicinski J, Ning S. US patent application: 20120149678A1   
  11. Oral pharmaceutical dosage forms  Scicinski J, van Osdol WW, Su, H-C, Arenberg, MH, Shah, J. US patent application: 20100260844A1   
  12. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof  Didsbury JR, Dyakonov T, Haydar SN, Jones ML, Li FF, Markworth CJ, Mathew J, Scheonen FJ, Scicinski JJ, Middlemiss D, Burns JF, Cabana LA, Collupy GC, Vanvliet DN.  US patent application: 20090264384A1   
  13. Compounds and Methods of Use Thereof  Didsbury JR, Dyakonov T, Haydar SN, Jones ML, Li FF, Markworth CJ, Mathew J, Scheonen FJ, Scicinski JJ, Middlemiss D, Burns JF, Cabana LA, Collupy GC, Vanvliet DN.  US patent application: 20080319044A1   
  14. Peptidase inhibitors  Royalty S, Burns JF, Scicinski JJ, Jagdmann GE, Foglesong RJ, Ring KG, Dyakonov T, Middlemiss D.  US patent application: 20080234292A1  

Janus Pharmaceutical Consulting LLC, Raleigh, NC 27615